We are building Hemab to reimagine care for people living with coagulation disorders who experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. By leveraging our deep understanding of the underlying biology of blood coagulation, we are developing targeted therapies for bleeding and thrombotic disorders like Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and others.